A population level analysis of second hematological malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma survivors in the era of targeted therapies
Hematological Oncology · 2023
DOI: 10.1002/hon.3192 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hematological Oncology, 2023. Verfasst von Rahul Mishra und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Non-Hodgkin, Hematologic Neoplasms, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
With improvement in survival after chronic lymphocytic leukemia (CLL) diagnosis, the real‐world burden of second hematological malignancies (SHM) has not been comprehensively assessed in recent era. We analyzed risk, incidence, and outcomes of SHM in CLL patients between 2000 and 2019 using SEER database. CLL patients had greater risk for hematological malignancies than general population [SIR, standardized incidence ratio (95% CI):2.58 (2.46–2.70); p < 0.05]. The risk for subsequent lymphoma increased by 1.75 folds in 2015–2019 compared to 2000–2004. The duration, after CLL diagnosis, of maximum risk for SHM decreased as 60–119 months for time‐period 2000–2004, 6–11 months for 2005–2009 to 2–5 months for 2010–2014 and 2015–2019. Incidence of SHM was 2.5% in CLL survivors (1736/70,346) with lymphoid SHM being more common than myeloid SHM, and DLBCL being the most common pathology ( n = 610, 35% of all SHM). Male sex, age ≤65 years at CLL diagnosis, and chemotherapy treatment were associated with higher risk for SHM. The median gap between CLL and SHM diagnoses was 46 months. The median survival for de‐novo‐AML, t‐MN, CML, and aggressive NHL was 63, 86, 95, and 96 months respectively. Although SHM remains rare, there is increased risk in recent era, likely due to improved survival in CLL patients, necessitating active surveillance strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology and Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA.
- Department of Internal Medicine, Saint Vincent Hospital, Worcester, Massachusetts, USA.
- Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
- Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
- Department of Internal Medicine, Allegheny General Hospital, Pittsburgh, Pennsylvania, USA.
ORCID-Profile: Rahul Mishra, Sumukh A Kumar
Zitieren
APA
Mishra, R., Dima, D., Kumar, S. A., Mian, A., Taneja, A., Karna, R., Caimi, P. F., Hill, B. T., Dean, R., & Jagadeesh, D. (2023). A population level analysis of second hematological malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma survivors in the era of targeted therapies. Hematological Oncology. https://doi.org/10.1002/hon.3192
Vancouver
Mishra R, Dima D, Kumar SA, Mian A, Taneja A, Karna R, et al. A population level analysis of second hematological malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma survivors in the era of targeted therapies. Hematological Oncology. 2023. doi:10.1002/hon.3192
BibTeX
@article{Mishra2023,
author = {Mishra, Rahul and Dima, Danai and Kumar, Sumukh A and Mian, Agrima and Taneja, Alankrita and Karna, Rahul and Caimi, Paolo F and Hill, Brian T and Dean, Robert and Jagadeesh, Deepa},
title = {A population level analysis of second hematological malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma survivors in the era of targeted therapies},
journal = {Hematological Oncology},
year = {2023},
doi = {10.1002/hon.3192}
}
EUVIMED